Jason Mast

N early a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the world's worst pathogens. “This is a crazy idea,” Sato said

By Jason Mast April 23, 2024 D ay One Biopharmaceuticals said Tuesday the Food and Drug Administration approved its pill for one of the most

By Jason Mast May 1, 2024 Three years ago, Moderna, flush with cash from Covid vaccine sales, announced it would start investing in the burgeoning field of gene editing.

A boy with Duchenne muscular dystrophy died after receiving a Pfizer experimental gene therapy. The company is pausing its trial in older boys.

By Jason Mast May 9, 2024 B ALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way.

By Jason Mast May 10, 2024 B ALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

By Jason Mast May 13, 2024 T wo years ago, Yiwei Shi was searching desperately for someone to build a drug for her newborn son, Leo.

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday.

By Jason Mast May 27, 2024 J apanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of

Ultragenyx said its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.